Position in TRLV
as of Jun 30, 2026
· filed Sep 2, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2026
1 quarter on record
Derivatives in TRLV
reported options exposure · as of Jun 30, 2026CallValue
$226,090
CallShares
23,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $1,255,675,844 across 65 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ELAN |
Elanco Animal Health Inc
|
9,668,611 | $237,944,516 | |
| 2 | ZTS |
Zoetis Inc.
|
3,188,263 | $229,108,578 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
304,692 | $165,091,266 | |
| 4 | LNTH |
Lantheus Holdings, Inc.
|
1,376,480 | $152,706,691 | |
| 5 | INDV |
Indivior Pharmaceuticals, Inc.
|
2,667,827 | $109,460,941 | |
| 6 | ALKS |
Alkermes plc.
|
1,645,101 | $86,203,291 | |
| 7 | SUPN |
Supernus Pharmaceuticals, Inc.
|
1,373,982 | $63,903,902 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
846,936 | $29,363,271 |
All Filings in TRLV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $226,090 | 23,000 | Call | Defined | 2026-09-02 | |
| No filing history on record for this holder in this stock. | ||||||